Persons with dispensed medicines; background; 2006-2020
| Sex | Age | Background and generation | Medicine group (ATC) | Periods | Persons with medicines, relative (%) |
|---|---|---|---|---|---|
| Total male and female | 0 to 64 years, standardised | Total background and generation | A Alimentary tract and metabolism | 2020 | 16.04 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | A02B Drugs for peptic ulcer and gord | 2020 | 6.76 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | A03B Belladonna and derivatives, plain | 2020 | 0.02 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | A03E Antispasmodics and anticholinergics | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | A04 Antiemetics and antinauseants | 2020 | 0.36 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | A04A Antiemetics and antinauseants | 2020 | 0.36 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | A05 Bile and liver therapy | 2020 | 0.07 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | A05C Bile therapy drugs and lipotropics | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | A10A Insulins and analogues | 2020 | 0.92 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | A11C Vit A and D, incl.combin.of the two | 2020 | 3.42 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | A11D Vitamin B1,and with vit. B6 and B12 | 2020 | 0.01 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | A16A Oth.aliment.tract and metabol.prod. | 2020 | 0.02 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | B Blood and blood forming organs | 2020 | 5.96 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | B02B Vitamin k and other hemostatics | 2020 | 0.03 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | B03B Vitamin B12 and folic acid | 2020 | 1.18 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | B05A Blood and related products | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | B05Z Hemodialytics and hemofiltrates | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | C01B Antiarrhythmics, class I and III | 2020 | 0.12 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | C07B Beta blocking agents and thiazides | 2020 | 0.05 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | D02 Emollients and protectives | 2020 | 4.59 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | D02A Emollients and protectives | 2020 | 4.59 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | D08 Antiseptics and disinfectants | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | D08A Antiseptics and disinfectants | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | G Genito urinary system and sex hormones | 2020 | 5.77 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | G03B Androgens | 2020 | 0.11 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | G03E Androgens / female sex hormon.comb. | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | G03H Antiandrogens | 2020 | 0.02 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | H05A Parathyroid hormones and analogues | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | J01E Sulfonamides and trimethoprim | 2020 | 0.53 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | J06 Immune sera and immunoglobulins | 2020 | 0.05 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | J07C Bacterial and viral vaccines,combi. | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | L Antineoplastic and immunomodul. agents | 2020 | 1.18 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | L02A Hormones and related agents | 2020 | 0.09 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | M02A Joint and muscular pain top. prod. | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | M05B Bone structure and mineralization . | 2020 | 0.37 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | N02B Other analgesics and antipyretics | 2020 | 0.03 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | N05C Hypnotics and sedatives | 2020 | 0.91 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | P01C Leishmaniasis and trypanosomiasis | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | P03B Insecticides and repellents | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | R05 Cough and cold preparations | 2020 | 1.77 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | R05F Cough suppressants and expectorants | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | S01F Mydriatics and cycloplegics | 2020 | 0.13 |
| Total male and female | 0 to 64 years, standardised | Total background and generation | S01G Decongestants and antiallergics | 2020 | 1.76 |
| Total male and female | 0 to 64 years, standardised | Dutch background | A Alimentary tract and metabolism | 2020 | 14.88 |
| Total male and female | 0 to 64 years, standardised | Dutch background | A02B Drugs for peptic ulcer and gord | 2020 | 6.57 |
| Total male and female | 0 to 64 years, standardised | Dutch background | A03B Belladonna and derivatives, plain | 2020 | 0.02 |
| Total male and female | 0 to 64 years, standardised | Dutch background | A03E Antispasmodics and anticholinergics | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Dutch background | A04 Antiemetics and antinauseants | 2020 | 0.37 |
| Total male and female | 0 to 64 years, standardised | Dutch background | A04A Antiemetics and antinauseants | 2020 | 0.37 |
| Total male and female | 0 to 64 years, standardised | Dutch background | A05 Bile and liver therapy | 2020 | 0.07 |
| Total male and female | 0 to 64 years, standardised | Dutch background | A05C Bile therapy drugs and lipotropics | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Dutch background | A10A Insulins and analogues | 2020 | 0.85 |
| Total male and female | 0 to 64 years, standardised | Dutch background | A11C Vit A and D, incl.combin.of the two | 2020 | 2.04 |
| Total male and female | 0 to 64 years, standardised | Dutch background | A11D Vitamin B1,and with vit. B6 and B12 | 2020 | 0.01 |
| Total male and female | 0 to 64 years, standardised | Dutch background | A16A Oth.aliment.tract and metabol.prod. | 2020 | 0.02 |
| Total male and female | 0 to 64 years, standardised | Dutch background | B Blood and blood forming organs | 2020 | 5.79 |
| Total male and female | 0 to 64 years, standardised | Dutch background | B02B Vitamin k and other hemostatics | 2020 | 0.03 |
| Total male and female | 0 to 64 years, standardised | Dutch background | B03B Vitamin B12 and folic acid | 2020 | 1.24 |
| Total male and female | 0 to 64 years, standardised | Dutch background | B05A Blood and related products | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Dutch background | B05Z Hemodialytics and hemofiltrates | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Dutch background | C01B Antiarrhythmics, class I and III | 2020 | 0.13 |
| Total male and female | 0 to 64 years, standardised | Dutch background | C07B Beta blocking agents and thiazides | 2020 | 0.05 |
| Total male and female | 0 to 64 years, standardised | Dutch background | D02 Emollients and protectives | 2020 | 4.26 |
| Total male and female | 0 to 64 years, standardised | Dutch background | D02A Emollients and protectives | 2020 | 4.26 |
| Total male and female | 0 to 64 years, standardised | Dutch background | D08 Antiseptics and disinfectants | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Dutch background | D08A Antiseptics and disinfectants | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Dutch background | G Genito urinary system and sex hormones | 2020 | 6.26 |
| Total male and female | 0 to 64 years, standardised | Dutch background | G03B Androgens | 2020 | 0.11 |
| Total male and female | 0 to 64 years, standardised | Dutch background | G03E Androgens / female sex hormon.comb. | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Dutch background | G03H Antiandrogens | 2020 | 0.02 |
| Total male and female | 0 to 64 years, standardised | Dutch background | H05A Parathyroid hormones and analogues | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Dutch background | J01E Sulfonamides and trimethoprim | 2020 | 0.57 |
| Total male and female | 0 to 64 years, standardised | Dutch background | J06 Immune sera and immunoglobulins | 2020 | 0.05 |
| Total male and female | 0 to 64 years, standardised | Dutch background | J07C Bacterial and viral vaccines,combi. | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Dutch background | L Antineoplastic and immunomodul. agents | 2020 | 1.23 |
| Total male and female | 0 to 64 years, standardised | Dutch background | L02A Hormones and related agents | 2020 | 0.09 |
| Total male and female | 0 to 64 years, standardised | Dutch background | M02A Joint and muscular pain top. prod. | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Dutch background | M05B Bone structure and mineralization . | 2020 | 0.38 |
| Total male and female | 0 to 64 years, standardised | Dutch background | N02B Other analgesics and antipyretics | 2020 | 0.02 |
| Total male and female | 0 to 64 years, standardised | Dutch background | N05C Hypnotics and sedatives | 2020 | 0.86 |
| Total male and female | 0 to 64 years, standardised | Dutch background | P01C Leishmaniasis and trypanosomiasis | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Dutch background | P03B Insecticides and repellents | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Dutch background | R05 Cough and cold preparations | 2020 | 1.69 |
| Total male and female | 0 to 64 years, standardised | Dutch background | R05F Cough suppressants and expectorants | 2020 | 0.00 |
| Total male and female | 0 to 64 years, standardised | Dutch background | S01F Mydriatics and cycloplegics | 2020 | 0.11 |
| Total male and female | 0 to 64 years, standardised | Dutch background | S01G Decongestants and antiallergics | 2020 | 1.57 |
| Source: CBS. | |||||
Table explanation
This table contains figures on the absolute number of persons to whom in the year concerned medicines were dispensed for which the costs are reimbursed under the statutory basic medical insurance. The figures are also expressed as a percentage of the total population in the category concerned. The population includes everybody registered in the Basic Registration of Persons (BRP) and living in the Netherlands at some point in the year concerned. Until 2010 the figures also included medicines dispensed to persons registered in the BRP, but no longer resident in the Netherlands.
Medicines provided to persons in hospitals and nursing homes are not included; medicines provided in residential homes for the elderly are included.
CBS is switching to a new population classification by origin. Greater emphasis will be placed on where a person was born and less on where their parents were born. The term ‘migration background’ will no longer be used in this regard. The main categories western/non-western will be replaced by categories based on continents and a few countries that share a specific migration history with the Netherlands. This classification will gradually been introduced in tables and publications with population by origin.
Data are broken down by medicine group, background, generation, age and sex.
Data available from 2006 to 2020.
Status of the figures:
All figures are definite.
Changes as of 14 December, 2022:
Figures for 2020 have been made final without change and the table has been stopped due to the introduction of the new classification of population by origin.
When will new figures be published?
Not applicable, the table has been stopped. This table will be replaced by the new table 'Persons with dispensed medicines; origin', see chapter 3.
Description topics
- Persons with medicines, relative
- Number of persons to whom medicines are dispensed in the year concerned that are reimbursed under the statutory basic medical insurance, expressed as a percentage of the total population of the category concerned registered in the Basic Registration of Persons (BRP) in that year.